Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2007

View Archived Issues

BKCa channel inhibition attenuates NO-induced dural and pial vasodilation in rats

Newly formed Proaegis Biosciences to develop drugs for ARDS and UC

Preclinical toxicology program for DTS-108 initiated at Diatos

FDA advisory committee recommends use of phosphate binders for hyperphosphatemia treatment

EMEA grants orphan medicinal product designation to picoplatin for SCLC

Phase III trial with Prochymal as first-line treatment for acute GVHD begins

bioMerieux receives FDA clearance for sepsis biomarker assay

Second phase II trial of ADL-5859 initiated for treatment of pain

Lilly and MacroGenics to develop teplizumab for autoimmune diseases

Phase IIa clinical study of MediciNova's MN-305 fails to achieve statistical significance

Complete phase Ib trial of brostallicin combination therapy in advanced solid tumors begins

Analysis reveals safe metabolic profile of bifeprunox

Aripiprazole effective as acute and maintenance therapy for bipolar disorder

RGH-188 pharmacokinetics, dopamine receptor occupancy studied in volunteers

LX-1031 well tolerated in early studies in humans

Novel agents for respiratory and allergic disorders disclosed in recent patent literature

Update on phase II and III studies of thrombin receptor antagonist

New treatment options for neurological disorders reported in recent patent literature

New calcium-activated potassium channel blockers emerge from Merck & Co. R&D

ASIC1a channels, key mediators of inflammatory pain hypersensitivity

GlaxoSmithKline receives approval for ArranonG in T-ALL and T-LBL

Acute heart failure approved as new indication for Sigmart Injection in Japan

Medtronic's drug-eluting stent receives CE Mark

DOR BioPharma receives FDA not approvable letter for orBec in GI GVHD indication

Johnson & Johnson reports third-quarter 2007 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...